Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724107 | 1.00 | CA14 (0.39) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27985727 | 0.98 | CA12 (0.38) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16634467 | 0.81 | MEN1 (0.33) | CA1CA2CA7HDAC1HDAC2 | |
| SCHEMBL18796420 | 0.81 | CA14 (0.41) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7021061 | 0.81 | CA14 (0.41) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30111551 | 0.81 | MEN1 (0.33) | CA1CA2CA7HDAC1HDAC2 | |
| SCHEMBL9455522 | 0.81 | CA14 (0.41) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9797670 | 0.78 | CA14 (0.39) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9797673 | 0.78 | CA14 (0.39) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5204515 | 0.78 | CA14 (0.39) | CA14CA12DGAT1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | disclosed |
| EP-1144365-B1 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| EP-1144365-A3 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6573295-B2 | Treating proliferative diseases, cancer, restenosis, osteoporosis, inflammation, aIlergies, or cardiovascular disease. | ARIAD PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | SHAKESPEARE WILLIAM C (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1144365-A2 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1064289-A1 | HETEROCYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000037429-A2 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999047529-A1 | HETEROCYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | ACP1, SRC, PPM1G | CA14 4771/4885CA12 4707/4885DGAT1 3659/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | CA14 2409/4885CA12 2520/4885DGAT1 1739/4885 |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | CA14 2522/4885CA12 2831/4885DGAT1 1834/4885 |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | CA14 2522/4885CA12 2831/4885DGAT1 1834/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | CA14 2409/4885CA12 2520/4885DGAT1 1739/4885 |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | CA14 4845/4885CA12 4850/4885DGAT1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.